Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 59

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

West Nile viral infection

Not yet recruiting

A Study of Doravirine for Early Treatment of West Nile Virus Infection in Patients at Risk of Disease Worsening

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Von Hippel-Lindau disease

Not yet recruiting

Study of Zirconium-89 Girentuximab as a Diagnostic Tool for Patients with Von-Hippel Lindau Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ZIRCONIUM (89ZR) GIRENTUXIMAB
  • Sponsor:Ospedale San Raffaele S.r.l.

Cognitive disorder

Not yet recruiting

Study of Citicoline to Prevent Cognitive Decline After Delirium in Older Adults with Hip Fracture

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Multiple sclerosis

Not yet recruiting

Study of Tenofovir Alafenamide as Add-on Treatment to Anti-CD20 Therapy in Multiple Sclerosis Patients to Reduce Neuronal Damage

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tenofovir Alafenamide
  • Sponsor:Oslo University Hospital HF

Cerebral haemorrhage

Not yet recruiting

Evaluation of Brain Inflammation Using 18F-DPA-714 PET Imaging in Patients with Intracerebral Hemorrhage

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Myasthenia gravis

Not yet recruiting

Study of TOL2 safety and immune response in patients with generalized myasthenia gravis

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Glucose

Neuronal ceroid lipofuscinosis

Not yet recruiting

First study of TTX-381 gene therapy safety in patients with eye problems caused by CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:TTX-381
  • Sponsor:Tern Therapeutics LLC

Urea cycle disorder

Not yet recruiting

Study of CMP-CPS-001 injection in healthy volunteers and patients with abnormal ornithine transcarbamylase (OTC) genotype for treating urea cycle disorders

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:AMMONIUM (15N) CHLORIDE
  • Sponsor:Camp4 Therapeutics Corp.

Hypoxic-ischaemic encephalopathy

Not yet recruiting

Study of intravenous melatonin safety and dosing in newborns with moderate to severe hypoxic-ischaemic encephalopathy receiving therapeutic hypothermia treatment

InvestigationalNo placebo
Countries:IrelandIreland
  • Participants:0–17 years
  • Substances:Melatonin
  • Sponsor:University College London

Systemic lupus erythematosus+6

Not yet recruiting

Study of RSV vaccines Arexvy and Abrysvo in patients with inflammatory rheumatic diseases receiving anti-rheumatic treatments

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:Region Skane

Piriformis syndrome

Not yet recruiting

Study of botulinum toxin injections to treat pain in patients with piriformis muscle syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Allodynia

Not yet recruiting

Safety and effectiveness study of PN6047 HCl in adults with peripheral neuropathic pain and mechanical allodynia

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Pharmnovo AB

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.